Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1674.2.

https://doi.org/10.1182/blood-2024-203060

Published: 2024

Journal Articles

Association of Body Composition Factors and Toxicity in Patients with Advanced Stage Hodgkin Lymphoma Receiving BV-AVD

Michele D. Stanchina, Russ Kuker, Sunwoo Han, Fei Yang, Mark K Polar, Jillian Lorayne Lykon, Tracy Crane, Melissa Lopez-Pentecost, Craig H. Moskowitz, Juan Pablo Alderuccio

Blood (2024) 144 (Supplement 1): 4423.

https://doi.org/10.1182/blood-2024-203734

Published: 2024

Journal Articles

High Complete Responses with Combination of Platinum-Based Regimen with BTK Inhibitors in Richter's Syndrome: University of Miami - Case Series

Georgios Pongas, Maryam Alasfour, Deborah Soong, Juan Pablo Alderuccio, Izidore S. Lossos

Blood (2024) 144 (Supplement 1): 6797.

https://doi.org/10.1182/blood-2024-211550

Published: 2024

Journal Articles

Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma

Juan Pablo Alderuccio, Alvaro J Alencar, Jonathan H. Schatz, Russ Kuker, David Sicre, Georgios Pongas, Isildinha M. Reis, Jay Y. Spiegel, Laura Medina Andara, Lazaros J. Lekakis, Joseph S. Gyedu, Jose Sandoval-Sus, Amer M. Beitinjaneh, Michele D. Stanchina, Asaad Trabolsi, Izidore S. Lossos, Joseph D. Rosenblatt, David S. Lessen, Craig H. Moskowitz

Blood (2024) 144 (Supplement 1): 337.

https://doi.org/10.1182/blood-2024-199093

Published: 2024

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response

Blood (2024) 144 (Supplement 1): 2981.

https://doi.org/10.1182/blood-2024-200975

Published: 2024

Journal Articles

Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma - Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study

Izidore S. Lossos, Geoffrey Shouse, Alvaro J Alencar, Safia Sawleh, David S. Lessen, Craig H. Moskowitz, Jennifer Rose Chapman-Fredricks, Isildinha M. Reis, Russ Kuker, Juan Pablo Alderuccio

Blood (2024) 144 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2024-200205

Published: 2024

Journal Articles

CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) - a Multicenter Retrospective Study

Ning Dong, Sushmita Khadka, Jose Sandoval-Sus, Carlos Silva Rondon, Ariel Perez, Tiba Al Sagheer, Madiha Iqbal, Juan Pablo Alderuccio, Cristian Rodriguez Arocho, Syeda Saba Kareem, Michael D. Jain, Julio C. Chavez

Blood (2024) 144 (Supplement 1): 3091.

https://doi.org/10.1182/blood-2024-203538

Published: 2024

Journal Articles

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis

Blood (2024) 144 (Supplement 1): 3751.

https://doi.org/10.1182/blood-2024-209383

Published: 2024

Journal Articles

Epcoritamab with R-CHOP Overcomes Poor Risk Features of High Total Metabolic Tumor Volume in High-Risk Large B-Cell Lymphoma

Juan Pablo Alderuccio, Russ Kuker, Mark K Polar, Fei Yang, Craig H. Moskowitz

Blood (2024) 144 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2024-209334

Published: 2024

Journal Articles

How I treat secondary CNS involvement by aggressive lymphomas

Juan Pablo Alderuccio, Lakshmi Nayak, Kate Cwynarski

Blood (2023) 142 (21): 1771–1783.

https://doi.org/10.1182/blood.2023020168

Published: 2023

Journal Articles

Cumulative Incidence, Predictors, and Outcomes of Transformation to Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Patients with Marginal Zone Lymphoma

Côme Bommier, Brian K. Link, Brianna Gysbers, Matthew J. Maurer, Melissa C. Larson, Arushi Khurana, Yucai Wang, Carrie Thompson, Dai Chihara, Juan Pablo Alderuccio, Jean L. Koff, Izidore S. Lossos, Grzegorz S. Nowakowski, Andrew L. Feldman, Thomas M. Habermann, Rebecca L. King, James R. Cerhan

Blood (2023) 142 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2023-186626

Published: 2023

Journal Articles

PET/CT Enables Appropriate Staging in Extranodal Marginal Zone Lymphoma

Blood (2023) 142 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2023-179478

Published: 2023

Journal Articles

Risk of Transformation By Frontline Management in Follicular Lymphoma and Marginal Zone Lymphoma: A US Population-Based Analysis

Jorge A Florindez, Dai Chihara, Isildinha M. Reis, Izidore S. Lossos, Juan Pablo Alderuccio

Blood (2023) 142 (Supplement 1): 383.

https://doi.org/10.1182/blood-2023-185313

Published: 2023

Journal Articles

A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma

Asaad Trabolsi, Narendranath Epperla, Kaitlin Annunzio, Dan Morgenstern Kaplan, Peter Doukas, Frederique St-Pierre, Brittany McCall, Lindsey Fitzgerald, Sunwoo Han, Isildinha M. Reis, Jennifer Rose Chapman-Fredricks, Khaled Alhamad, Thomas Ollila, Reem Karmali, Izidore S. Lossos, Juan Pablo Alderuccio

Blood (2023) 142 (Supplement 1): 3770.

https://doi.org/10.1182/blood-2023-173905

Published: 2023

Journal Articles

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Blood (2023) 142 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2023-179061

Published: 2023

Journal Articles

Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma - a Phase 2 Study

Juan Pablo Alderuccio, Alvaro J. Alencar, Jonathan H. Schatz, Russ Kuker, Georgio Pongas, Isildinha M. Reis, Jay Y. Spiegel, Laura Medina Andara, Lazaros J. Lekakis, Joseph S. Gyedu, Jose Sandoval-Sus, Amer M. Beitinjaneh, Nathalie Padron, Izidore S. Lossos, Joseph D. Rosenblatt, David S. Lessen, Craig H. Moskowitz

Blood (2023) 142 (Supplement 1): 984.

https://doi.org/10.1182/blood-2023-178825

Published: 2023

Journal Articles

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Juan Pablo Alderuccio, Isildinha M. Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R. Chapman, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos

Blood (2023) 141 (15): 1888–1893.

https://doi.org/10.1182/blood.2022019294

Published: 2023

Includes: Supplemental data

Journal Articles

Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Blood (2022) 140 (Supplement 1): 6650–6652.

https://doi.org/10.1182/blood-2022-162758

Published: 2022

Journal Articles

Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Juan Pablo Alderuccio, Isildinha M Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R Chapman-Fredricks, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos

Blood (2022) 140 (Supplement 1): 9340–9341.

https://doi.org/10.1182/blood-2022-162688

Published: 2022

NARROW

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Association of Body Composition Factors and Toxicity in Patients with Advanced Stage Hodgkin Lymphoma Receiving BV-AVD

High Complete Responses with Combination of Platinum-Based Regimen with BTK Inhibitors in Richter's Syndrome: University of Miami - Case Series

Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response

Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma - Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study

CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) - a Multicenter Retrospective Study

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis

Epcoritamab with R-CHOP Overcomes Poor Risk Features of High Total Metabolic Tumor Volume in High-Risk Large B-Cell Lymphoma

How I treat secondary CNS involvement by aggressive lymphomas

Cumulative Incidence, Predictors, and Outcomes of Transformation to Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Patients with Marginal Zone Lymphoma

PET/CT Enables Appropriate Staging in Extranodal Marginal Zone Lymphoma

Risk of Transformation By Frontline Management in Follicular Lymphoma and Marginal Zone Lymphoma: A US Population-Based Analysis

A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma - a Phase 2 Study

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only